{"id":"placebo-for-macitentan","safety":{"commonSideEffects":[]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Placebos are used as control comparators in clinical trials to measure the efficacy of an active drug by comparison. In this case, it serves as the control arm in trials evaluating macitentan, an endothelin receptor antagonist. Any observed effects are attributable to the placebo effect or natural disease progression rather than direct molecular action.","oneSentence":"A placebo is an inert substance with no active pharmacological mechanism.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:00:55.793Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Control comparator in macitentan clinical trials"}]},"trialDetails":[{"nctId":"NCT04273945","phase":"PHASE3","title":"Outcome Study Assessing a 75 Milligrams (mg) Dose of Macitentan in Patients With Pulmonary Arterial Hypertension","status":"ACTIVE_NOT_RECRUITING","sponsor":"Actelion","startDate":"2020-06-30","conditions":"Pulmonary Arterial Hypertension","enrollment":935},{"nctId":"NCT03904693","phase":"PHASE3","title":"Clinical Study to Compare the Efficacy and Safety of Macitentan and Tadalafil Monotherapies With the Corresponding Fixed-dose Combination Therapy in Subjects With Pulmonary Arterial Hypertension (PAH)","status":"COMPLETED","sponsor":"Actelion","startDate":"2019-07-29","conditions":"Pulmonary Arterial Hypertension (PAH) (WHO Group 1 PH)","enrollment":187},{"nctId":"NCT04271475","phase":"PHASE3","title":"A Study to Evaluate Efficacy and Safety of Macitentan 75 mg in Inoperable or Persistent/Recurrent Chronic Thromboembolic Pulmonary Hypertension","status":"TERMINATED","sponsor":"Actelion","startDate":"2020-07-07","conditions":"Chronic Thromboembolic Pulmonary Hypertension","enrollment":127},{"nctId":"NCT03153111","phase":"PHASE2","title":"A Study to Evaluate Whether Macitentan is an Effective and Safe Treatment for Patients With Heart Failure With Preserved Ejection Fraction and Pulmonary Vascular Disease","status":"COMPLETED","sponsor":"Actelion","startDate":"2017-07-11","conditions":"Heart Failure With Preserved Ejection Fraction","enrollment":143},{"nctId":"NCT01474122","phase":"PHASE3","title":"Macitentan for the Treatment of Digital Ulcers in Systemic Sclerosis Patients","status":"TERMINATED","sponsor":"Actelion","startDate":"2011-12","conditions":"Digital Ulcers","enrollment":265},{"nctId":"NCT05946811","phase":"PHASE3","title":"Macitentan to Prevent PRVO","status":"WITHDRAWN","sponsor":"University of Maryland, Baltimore","startDate":"2024-05-01","conditions":"Pulmonary Embolism","enrollment":""},{"nctId":"NCT01824290","phase":"PHASE3","title":"A Study of Tadalafil in Pediatric Participants With Pulmonary Arterial Hypertension (PAH)","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2014-02-05","conditions":"Hypertension, Pulmonary","enrollment":35},{"nctId":"NCT02893176","phase":"PHASE4","title":"Macitentan in the Treatment of Organ Rejection After Lung Transplantation","status":"WITHDRAWN","sponsor":"University of California, Los Angeles","startDate":"2016-09","conditions":"Lung Transplant Rejection","enrollment":""},{"nctId":"NCT01474109","phase":"PHASE3","title":"Macitentan for the Treatment of Digital Ulcers in Systemic Sclerosis Patients","status":"COMPLETED","sponsor":"Actelion","startDate":"2011-12","conditions":"Systemic Sclerosis, Ulcers","enrollment":289}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":66,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"placebo (for macitentan)","genericName":"placebo (for macitentan)","companyName":"University of California, Los Angeles","companyId":"university-of-california-los-angeles","modality":"Small molecule","firstApprovalDate":"","aiSummary":"A placebo is an inert substance with no active pharmacological mechanism. Used for Control comparator in macitentan clinical trials.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":false,"trials":true,"score":3}}